Holen Sie sich die Stockscreener-App
1.05
0.00%
0.00
Handel nachbörslich:
1.05
Schlusskurs vom Vortag:
$1.05
Offen:
$1.06
24-Stunden-Volumen:
43,495
Relative Volume:
0.24
Marktkapitalisierung:
$31.68M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-60.70M
KGV:
-0.5147
EPS:
-2.04
Netto-Cashflow:
$-61.05M
1W Leistung:
-2.33%
1M Leistung:
-0.94%
6M Leistung:
-1.87%
1J Leistung:
-3.67%
1-Tages-Spanne:
$1.05
$1.09
1-Wochen-Bereich:
$1.05
$1.10
52-Wochen-Spanne:
$0.95
$1.675
An 2 Therapeutics Inc Stock (ANTX) Company Profile
Firmenname
An 2 Therapeutics Inc
Sektor
Branche
Telefon
(650) 331-9090
Adresse
1800 EL CAMINO REAL, SUITE D, MENLO PARK
Vergleichen Sie ANTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
1.05 | 31.68M | 0 | -60.70M | -61.05M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-09 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2024-08-09 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-07-03 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-04-02 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2024-02-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-12 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-02-12 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-01-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
Alle ansehen
An 2 Therapeutics Inc Aktie (ANTX) Neueste Nachrichten
Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
Windtree Therapeutics, Inc. Reports Positive Interim Analysis for Istaroxime in Phase 2 Study of Cardiogenic Shock - Quiver Quantitative
BioXcel Therapeutics Completes Phase 3 Trial, Awaits FDA Decision - StocksToTrade
Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug - MSN
BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewswire
Sangamo Therapeutics Announces Positive Phase 1/2 STAAR Study Results for Fabry Gene Therapy - Yahoo Finance
Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis - Newsfile
Cognition Therapeutics, Inc. Reports Promising Results for Zervimesine in Phase 2 Alzheimer’s and Dementia with Lewy Bodies Studies - Nasdaq
Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC - GlobeNewswire
Compass Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Ovid Therapeutics (NASDAQ:OVID) Stock Price Down 2% – Time to Sell? - Defense World
Cognition Therapeutics, Inc. Discusses Phase 2 Results and Future Plans for Zervimesine Treatment in Alzheimer's Disease with FDA - Nasdaq
Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease - GlobeNewswire
Breakthrough for Alzheimer's Treatment: FDA Meeting Clears Path for Zervimesine Phase 3 Program - Stock Titan
Unicycive Therapeutics (NASDAQ:UNCY) Trading 2% Higher – Time to Buy? - Defense World
Avenzo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate - Business Wire
Apogee Therapeutics Announces Positive 16-Week Data from - GlobeNewswire
New Atopic Dermatitis Drug Shows Record-Breaking 67% Success Rate, Could Reduce Injections to Just 4 Times Per Year - Stock Titan
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II) - GlobeNewswire
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025 - GlobeNewswire
Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer's Trial Data - Benzinga
Alembic Pharmaceuticals up 2% as arm acquires Utility Therapeutics; details - Business Standard
Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement - GlobeNewswire
Cognition Therapeutics Reports Over 50% Enrollment in Phase 2 START Study for Alzheimer's Treatment - Nasdaq
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program - Yahoo Finance
Allarity Therapeutics Announces Dosing of Second Patient in - GlobeNewswire
Cognition Therapeutics Provides Regulatory Update on - GlobeNewswire
Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - Business Wire
Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency - Yahoo Finance
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO - GlobeNewswire
$452M Deal: Processa's Phase 2 Gastroparesis Drug Shows Promise, Attracts Major Licensing Interest - Stock Titan
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 - GlobeNewswire
Layoff Tracker: ADC Therapeutics Cutting 30% of Staff, Closing London Research Facility - BioSpace
BioRestorative Therapies, Inc. Reports Promising Phase 2 Clinical Trial Results for BRTX-100 at ISSCR 2025 Annual Meeting - Nasdaq
Celldex Presents Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci Congress 2025 - marketscreener.com
Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
Intensity Therapeutics, Inc. Announces Pricing of Public Offering - PR Newswire
Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock - PR Newswire
Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study - Morningstar
Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-023, a Potential Best-in-Class, Novel CDK4 Selective Inhibitor - Business Wire
Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate - Business Wire
Aclaris Therapeutics, Inc. Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - marketscreener.com
Lyra Therapeutics Reports Positive Results From The Enlighten 2 Phase 3 Trial Of Lyr-210 - marketscreener.com
Allarity Therapeutics Announces First Patient Enrolled in - GlobeNewswire
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer - The Manila Times
Sapience Therapeutics Provides Data Update from Phase 2 Trial of Lucicebtide in Patients with Glioblastoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - PR Newswire
Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - GlobeNewswire
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) - GlobeNewswire
Certain Stock Options of Edgewise Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-JUN-2025. - marketscreener.com
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology - The Malaysian Reserve
Kymera Therapeutics, Inc. (KYMR) to Announce KT-621 Phase 1 Results on June 2, 2025 - Insider Monkey
Finanzdaten der An 2 Therapeutics Inc-Aktie (ANTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):